CORDIS · 101136835 · HORIZON
HIT-GLIO Targeting tumour-host interactions in paediatric malignant gliomas to reinvigorate immunity and improve radio- and immunotherapy efficacy
Coordinator: INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK (PL)
Paediatric high-grade gliomas (pHGGs) are malignant, deadly tumours developing in infants and children. Mutations in histone coding genes disturb epigenetic regulation and in cooperation with other oncogenes promote tumour initiation and progression. pHGGs are fast-growing and diffusive which makes them hard to remove or treat. Surgery (unattainable in midline brain regions) and radiotherapy (RT) remain the only option with transient benefits as median survival is 9-15 months. Those tumours are immunosuppressed, thus immunotherapy is ineffective. We propose that knowledge of tumour-host inter…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
EU contribution: €9.7M awarded to the consortium. The project runs over approximately 4 years from 2023-12-01 to 2027-11-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from PL
see all →- UASEEDs — SEEDS OF BRAVERY: supporting Ukraine’s tech start-up scene and bringing it closer to the EU101104445 · HORIZON · €20.0M
- P4Health — Centre of Excellence for Precise Phenotyping and BioDataBanking101136375 · HORIZON · €15.0M
- Astrocent Plus — Astrocent Plus -- Particle Astrophysics Science and Technology Centre101137080 · HORIZON · €15.0M
- TRIO-VI CoE — Translational Research and Innovation in Ophthalmology Vision - Centre of Excellence101136570 · HORIZON · €15.0M
- QuantERA III — QUANTERA III RIA: COFUND IN QUANTUM TECHNOLOGIES101212998 · HORIZON · €15.0M
- QuantERA II — QuantERA II ERA-NET Cofund in Quantum Technologies101017733 · H2020 · €15.0M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €9.7M toward a total project budget of €9.7M.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call HORIZON-MISS-2023-CANCER-01.
- Who coordinates the project?
- The project is coordinated by INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK (PL).
- What is the project timeline?
- The project runs from 2023-12-01 to 2027-11-30 — approximately 4 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101136835.